Drug Discovery Today 2012 v.17 №19-20

London, UK.: Elsevier. — 112 p.Since its launch in 1996, Drug Discovery Today has been at the cutting edge of the science underpinning drug discovery and development. Drug Discovery Today delivers highly current reviews to the readers, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.Contents:
Foundation.
Translational CNS medicines research.
Alan M. Palmer and Mohammad S. Alavijeh.
Does transbilayer diffusion have a role in membrane transport of drugs?
Stefan Balaz.
Keynote.
Drug discovery in pharmaceutical industry: productivity challenges and trends.
Ish Khanna.
Gene to screen.
The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells.
Tullio Florio and Federica Barbieri.
Recent progress in structure-based anti-infl uenza drug design.
Juan Du, Timothy A. Cross and Huan-Xiang Zhou.
Informatics.
Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem.
Ge-Fei Hao, Guang-Fu Yang and Chang-Guo Zhan.
Post screen.
Gallium as a potential candidate for treatment of osteoporosis.
E. Verron, J.M. Bouler and J.C. Scimeca.
Subtleties in GPCR drug discovery: a medicinal chemistry perspective.
Masahiko Fujioka and Naoki Omori.
Improving drug penetration to curb tumor drug resistance.
Fabrizio Marcucci and Angelo Corti.
Silica-based nanoparticles for biomedical applications.
Ahmad Bitar, Nasir M. Ahmad, Hatem Fessi and Abdelhamid Elaissari.